EchoCath gains clearance for EchoFlow

Article

Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s

Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s applications include assessing the condition of blood vessels during and after surgery, determining proper placement of bypass grafts, and monitoring blood flow for implantable devices such as pacemakers, according to the Princeton, NJ-based firm. EchoCath will initially market EchoFlow to vascular surgeons for measuring blood-flow velocities but is also seeking corporate alliances for applications outside vascular surgery.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.